Patent US4876349A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4876349A Expired / Lapsed US ⏱️ 0.0 years remaining

Tetrahydronaphthalene and indane derivatives

Assignee: F Hoffmann La Roche AG
•
Filing: 1987-07-10
•
Granted: 1989-10-24
•
Expires: 2007-07-10
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The compounds of the formula ##STR1## wherein X and Y are independently --CH 2 -- or >C(CH 3 ) 2 ; Z is --CHR 8 --, >Co, >CR 8 OR 7 , --CHR 8 --CHR 8 --, --CHOR 7 --CH 2 --, --CO--CHOR 7 or --CHOR 7 --CHOR 7 --R 1 is a 5- or 6-membered, monocyclic heterocyclic group which optionally can be C-substituted by halogen, lower-alkyl, lower-alkoxy, acyloxy, nitro, hydroxy, amino, lower-alkylamino or di-lower-alkylamino and/or which can be substituted on a ring --NH-- group by lower-alkyl; R 2 and R 3 are independently hydrogen, lower-alkyl, trifluoromethyl or halogen and one of R 2 and R 3 always is trifluoromethyl or lower-alkyl; R 4 and R 5 are independently hydrogen, alkyl, alkoxy or halogen; R 6 is hydrogen, lower-alkyl or --OR 7 ; R 7 is hydrogen, lower-alkyl or acyl; R 8 is hydrogen or lower-alkyl; and R 7 and R 8 can be the same or different from one another. are useful for the treatment of neoplasms and dermatoses in mammals. The compounds can be manufactured from a corresponding bicyclic component and a heterocyclic component containing the residue R 1 by a Wittig, Horner or Grignard reaction and the optional subsequent transformation of reactive groups.

Inventors

  • 👤 Michael Klaus
  • 👤 Ekkehard Weiss

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-30 23:17
CPC Classifications
C; C07; C07D; C07D209/00; C07D209/02; C07D209/04; C07D213/00; C07D213/02; C07D213/04; C07D213/06; C07D213/16; A; A61; A61P; A61P17/00; A61P29/00; A61P35/00; A61P37/00; A61P37/08; C07D239/00; C07D239/02; C07D239/24; C07D239/26; C07D307/00; C07D307/02; C07D307/34; C07D307/36; C07D333/00; C07D333/02; C07D333/04; C07D333/06; C07D333/08

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 113 words
A compound of the formula ##STR4## wherein X and Y are independently --CH 2 -- or >C(CH 3 ) 2 ; Z is --CHR 8 -- or --CHR 8 --CHR 8 --; R 1 is pyridyl, unsubstituted; R 2 and R 3 are independently hydrogen, lower-alkyl, trifluoromethyl or halogen and one of R 2 and R 3 is always trifluoromethyl or lower-alkyl; R 4 and R 5 are independently hydrogen, alkyl, alkoxy or halogen; R 6 is hydrogen, lower-alkyl or a residue --OR 7 ; R 7 is hydrogen, lower-alkyl or acyl; R 8 is hydrogen or lower-alkyl; and R 7 and R 8 can be the same or different from one another.
Claim 2
Dependent Claim 113 words
A compound of the formula ##STR4## wherein X and Y are independently --CH 2 -- or >C(CH 3 ) 2 ; Z is --CHR 8 -- or --CHR 8 --CHR 8 --; R 1 is pyridyl, unsubstituted; R 2 and R 3 are independently hydrogen, lower-alkyl, trifluoromethyl or halogen and one of R 2 and R 3 is always trifluoromethyl or lower-alkyl; R 4 and R 5 are independently hydrogen, alkyl, alkoxy or halogen; R 6 is hydrogen, lower-alkyl or a residue --OR 7 ; R 7 is hydrogen, lower-alkyl or acyl; R 8 is hydrogen or lower-alkyl; and R 7 and R 8 can be the same or different from one another.
Claim 3
Dependent Claim 58 words
A compounds in accordance with claim 1 in which X and Y are >C(CH 3 ) 2 ; Z is --CH 2 --CH 2 --; R 1 is an unsubstituted monocyclic heterocyclic group; R 2 , R 5 and R 6 are hydrogen; and R 4 is hydrogen or alkyl or alkoxy having up to 10 carbon atoms.
Claim 4
Dependent Claim 3 words
The compound, 3-[(E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]pyridine.
Claim 5
Dependent Claim 3 words
The compound, 3-[(E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]pyridine.
Claim 6
Dependent Claim 3 words
The compound, 2-[(E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]pyridine.
Claim 7
Dependent Claim 3 words
The compound, 2-[(E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]pyridine.
Claim 8
Dependent Claim 3 words
The compound 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]pyridine.
Claim 9
Dependent Claim 3 words
The compound 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]pyridine.
Claim 10
Dependent Claim 126 words
A pharmaceutical composition comprising as the active substance a compound of the formula ##STR5## wherein X and Y are independently --CH 2 -- or >C(CH 3 ) 2 ; Z is --CHR 8 -- or --CHR 8 --CHR 8 --; R 1 is pyridyl, unsubstituted; R 2 and R 3 are independently hydrogen, lower-alkyl, trifluoromethyl or halogen and one of R 2 and R 3 is always trifluoromethyl or lower-alkyl; R 4 and R 5 are independently hydrogen, alkyl, alkoxy or halogen; R 6 is hydrogen, lower-alkyl or a residue --OR 7 ; R 7 is hydrogen, lower-alkyl or acyl; R 8 is hydrogen or lower-alkyl; and R 7 and R 8 can be the same or different from one another, and a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim 126 words
A pharmaceutical composition comprising as the active substance a compound of the formula ##STR5## wherein X and Y are independently --CH 2 -- or >C(CH 3 ) 2 ; Z is --CHR 8 -- or --CHR 8 --CHR 8 --; R 1 is pyridyl, unsubstituted; R 2 and R 3 are independently hydrogen, lower-alkyl, trifluoromethyl or halogen and one of R 2 and R 3 is always trifluoromethyl or lower-alkyl; R 4 and R 5 are independently hydrogen, alkyl, alkoxy or halogen; R 6 is hydrogen, lower-alkyl or a residue --OR 7 ; R 7 is hydrogen, lower-alkyl or acyl; R 8 is hydrogen or lower-alkyl; and R 7 and R 8 can be the same or different from one another, and a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim 64 words
A composition in accordance with claim 6, in which for the compound of formula I, X and Y are >C(CH 3 ) 2 ; Z is --CH 2 --CH 2 --; R 1 is an unsubstituted monocyclic heterocyclic group; R 2 , R 5 and R 6 are hydrogen; and R 4 is hydrogen or alkyl or alkoxy having up to 10 carbon atoms.
Claim 13
Dependent Claim 27 words
A composition in accordance with claim 6 in which for the compound of formula I is a member of the group consisting of 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]pyridine, 3-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]pyridine, and 2-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]pyridine.
Claim 14
Independent Claim 138 words
A method for treating neoplasms and dermotoses in mammals which comprises administering an effective amount of a pharmaceutical composition containing a compound of the formula ##STR6## wherein X and Y are independently --CH 2 -- or >C(CH 3 ) 2 ; Z is --CHR 8 -- or CHR 8 --CHR 8 --; R 1 is pyridyl, unsubstituted; R 2 and R 3 are independently hydrogen, lower-alkyl, trifluoromethyl or halogen and one of R 2 and R 3 is always trifluoromethyl or lower-alkyl; R 4 and R 5 are independently hydrogen, alkyl, alkoxy or halogen; R 6 is hydrogen, lower-alkyl or a residue --OR 7 ; R 7 is hydrogen, lower-alkyl or acyl; R 8 is hydrogen or lower-alkyl; and R 7 and R 8 can be the same or different from one another, and a pharmaceutically acceptable carrier.
Claim 15
Independent Claim 138 words
A method for treating neoplasms and dermotoses in mammals which comprises administering an effective amount of a pharmaceutical composition containing a compound of the formula ##STR6## wherein X and Y are independently --CH 2 -- or >C(CH 3 ) 2 ; Z is --CHR 8 -- or CHR 8 --CHR 8 --; R 1 is pyridyl, unsubstituted; R 2 and R 3 are independently hydrogen, lower-alkyl, trifluoromethyl or halogen and one of R 2 and R 3 is always trifluoromethyl or lower-alkyl; R 4 and R 5 are independently hydrogen, alkyl, alkoxy or halogen; R 6 is hydrogen, lower-alkyl or a residue --OR 7 ; R 7 is hydrogen, lower-alkyl or acyl; R 8 is hydrogen or lower-alkyl; and R 7 and R 8 can be the same or different from one another, and a pharmaceutically acceptable carrier.
Claim 16
Dependent Claim 64 words
A method in accordance with claim 9, in which for the compound of formula I, X and Y are >C(CH 3 ) 2 ; Z is --CH 2 --CH 2 --; R 1 is an unsubstituted monocyclic heterocyclic group; R 2 , R 5 and R 6 are hydrogen; and R 4 is hydrogen or alkyl or alkoxy having up to 10 carbon atoms.
Claim 17
Dependent Claim 27 words
A method in accordance with claim 9, in which the compound of formula I employed is a member of the group consisting of: 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-propenyl]pyridine, 3-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]pyridine, and 2-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]pyridine.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1992-10-23 1993-04-24 1993-10-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1996-10-23 1997-04-24 1997-10-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2000-10-23 2001-04-24 2001-10-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag